GlassScriptPhysician profile
Lawrence Wilner
NPI 1518068709
$3,957.05
in general payments reported to CMS, 2019-2025
42 companies · $68.56 in 2025
The $68.56 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $280 · 2021: $890 · 2022: $755 · 2023: $1,167 · 2024: $327 · 2025: $68.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,501 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,500.74 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $581.25 | 2019-2025 | Airsupra, Breztri |
| Abbvie INC. | $396.50 | 2021-2025 | Vraylar, Qulipta |
| Novo Nordisk INC | $340.00 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $302.52 | 2020-2024 | Veozah, Myrbetriq |
| Amgen INC. | $293.48 | 2019-2024 | Evenity, Krystexxa, Prolia |
| Eisai INC. | $194.65 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $190.84 | 2023 | Spravato |
| Gilead Sciences, INC. | $175.26 | 2023 | Descovy |
| Nevro Corp. | $136.48 | 2022-2023 | Senza |
| Alkermes, INC. | $117.77 | 2022-2024 | Aristada, Lybalvi |
| Glaxosmithkline, LLC. | $115.48 | 2020-2023 | Shingrix, Trelegy Ellipta |
| Biohaven Pharmaceuticals, INC. | $107.48 | 2020-2021 | |
| Pfizer INC. | $106.31 | 2021-2024 | |
| Optinose US, INC. | $71.56 | 2020-2022 | |
| Viiv Healthcare Company | $70.13 | 2022-2023 | Apretude |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Wilner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.